Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Aug;15(4):266-71.
doi: 10.1007/s11655-009-0266-x. Epub 2009 Aug 18.

Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension

Affiliations
Randomized Controlled Trial

Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension

Li Lu et al. Chin J Integr Med. 2009 Aug.

Abstract

Objective: To investigate the impacts of Xuezhikang (XZK) or pravastatin combined with antihypertensive drugs on circulating endothelial progenitor cells (CEPCs) in essential hypertensive (EH) patients.

Methods: Eighty-eight EH patients were enrolled into the study and randomly assigned to the antihypertensive drug treatment group (ATH group, 29 cases), the pravastatin treatment group (PRA group, 29 cases) and the Xuezhikang treatment group (XZK group, 30 cases). Patients in the 3 groups were treated with routine antihypertensive drugs. In addition, pravastatin and Xuezhikang were given to the patients in the PRA group and XZK group, respectively. After an eight-week treatment, CEPCs were counted using a laser scanning confocal microscope, and their proliferation function was evaluated by the MTT colorimetric assay and the adherent cell number was counted to estimate the adhesion function.

Results: After the treatment, CEPCs in the PRA group (116.60+/-5.70) and XZK group (114.40+/-6.55) was significantly higher than that in the ATH group (88.00+/-6.32, P<0.01). CEPCs proliferation capability and the adhesion function in the PRA group (0.406+/-0.016, 33.60+/-4.26) and XZK group (0.415+/-0.018, 34.30+/-3.77) were obviously superior to those in the ATH group (0.333+/-0.021, P<0.01; 23.30+/-3.19, P<0.01). No significant difference was found between the pravastatin group and the XZK group.

Conclusions: Combined use of XZK or pravastatin with the anti-hypertensive therapy could increase the CEPCs number and improve their function in EH patients with the blood pressure controlled by antihypertensive drugs, leading to benefits independent of pressure-lowering effects.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Science. 1997 Feb 14;275(5302):964-7 - PubMed
    1. Hypertens Res. 2003 Sep;26(9):699-704 - PubMed
    1. N Engl J Med. 2005 Sep 8;353(10):999-1007 - PubMed
    1. Circulation. 2003 Sep 23;108(12):1520-6 - PubMed
    1. Circulation. 2004 Aug 24;110(8):915-20 - PubMed

Publication types

MeSH terms

LinkOut - more resources